Journal article · 2026 · Open access

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

Steven B. Heymsfield, Louis J. Aronne, Penelope Montgomery, Lloyd B. Klickstein, Laura A. Coleman, Kiran Dole, Linda Mindeholm, Susan E. Spruill, Xingyuan Li, Kenneth M. Attie, for the BELIEVE trial investigators

Nature Medicine, 32(3), 869–882 · Published 1 March 2026 · DOI 10.1038/s41591-026-04204-0

Open full textCite this paper

In brief

“Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial” is a 2026 journal article by Steven B. Heymsfield and 10 co-authors, published in Nature Medicine. OpenAlex counts 100 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.

Citations
100
Most cited in
2026 (100)
Field-weighted impact
247.84
References
30
Authors
11

Abstract

Bimagrumab is an investigational antibody targeting type II activin receptors, intended to reduce total body and visceral fat mass and promote muscle growth. In this double-blind, placebo-controlled phase 2, trial, 507 adults with obesity (body mass index ≥30 kg m − 2 or ≥27 kg m − 2 with at least one obesity-associated complication (excluding diabetes) were randomized to nine groups (1:1:1:1:1:1:1:1:1 ratio) to receive treatment for 48 weeks: placebo, bimagrumab (10 mg kg −1 or 30 mg kg −1 intravenously every 12 weeks), semaglutide (1.0 mg or 2.4 mg subcutaneously once a week) and combinations thereof. An open-label treatment extension to week 72 followed. Randomization was stratified by sex across the treatment groups. The primary and secondary endpoints were absolute change from baseline in body weight at week 48 and week 72, respectively. The least squares mean absolute changes in body weight at week 48 were −9.3 kg (bimagrumab 30 mg kg −1 ), −14.2 kg (semaglutide 2.4 mg) and −17.8 kg (bimagrumab 30 mg kg −1 plus semaglutide 2.4 mg—that is, high-dose combination) versus −3.3 kg (placebo) (all P < 0.001 versus placebo). Continued improvements were observed through week 72. Common adverse events for bimagrumab included muscle spasms, diarrhea and acne, and semaglutide was associated with nausea, diarrhea, constipation and fatigue. Bimagrumab plus semaglutide resulted in substantial reductions in body weight, and safety was consistent with the known safety profiles of both drugs. ClinicalTrials.gov identifier: NCT05616013 .

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Heymsfield, S. B., Aronne, L. J., Montgomery, P., Klickstein, L. B., Coleman, L. A., Dole, K., Mindeholm, L., Spruill, S. E., Li, X., Attie, K. M., & for the BELIEVE trial investigators. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine, 32(3), 869–882. https://doi.org/10.1038/s41591-026-04204-0

MLA 9

Heymsfield, Steven B., et al. “Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.” Nature Medicine, vol. 32, no. 3, 2026, pp. 869–882. https://doi.org/10.1038/s41591-026-04204-0.

Chicago

Heymsfield, Steven B., Louis J. Aronne, Penelope Montgomery, Lloyd B. Klickstein, Laura A. Coleman, Kiran Dole, Linda Mindeholm, et al. 2026. “Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.” Nature Medicine 32 (3): 869–882. https://doi.org/10.1038/s41591-026-04204-0.

Harvard

Heymsfield, S. B. et al. (2026) ‘Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial’, Nature Medicine, 32(3), pp. 869–882. doi:10.1038/s41591-026-04204-0.

IEEE

S. B. Heymsfield et al., “Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial,” Nature Medicine, vol. 32, no. 3, pp. 869–882, 2026, doi: 10.1038/s41591-026-04204-0.

BibTeX

@article{heymsfield2026bimagrumab,
  title     = {{Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial}},
  author    = {Heymsfield, Steven B. and Aronne, Louis J. and Montgomery, Penelope and Klickstein, Lloyd B. and Coleman, Laura A. and Dole, Kiran and Mindeholm, Linda and Spruill, Susan E. and Li, Xingyuan and Attie, Kenneth M. and for the BELIEVE trial investigators},
  journal   = {Nature Medicine},
  year      = {2026},
  volume    = {32},
  number    = {3},
  pages     = {869--882},
  doi       = {10.1038/s41591-026-04204-0},
  url       = {https://doi.org/10.1038/s41591-026-04204-0}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment

  • bimagrumab
  • semaglutide
  • obesity treatment
  • weight loss
  • combination therapy
  • visceral fat
  • muscle growth
  • adverse events

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Heymsfield, S. B., Aronne, L. J., Montgomery, P., Klickstein, L. B., Coleman, L. A., Dole, K., Mindeholm, L., Spruill, S. E., Li, X., Attie, K. M., & for the BELIEVE trial investigators. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine, 32(3), 869–882. https://doi.org/10.1038/s41591-026-04204-0

How many times has this paper been cited?

100 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the full text from this page.

Who wrote this paper?

Steven B. Heymsfield, Louis J. Aronne, Penelope Montgomery, Lloyd B. Klickstein, Laura A. Coleman, Kiran Dole, Linda Mindeholm, Susan E. Spruill, Xingyuan Li, Kenneth M. Attie, for the BELIEVE trial investigators.

What is the DOI of this paper?

10.1038/s41591-026-04204-0, permanently at https://doi.org/10.1038/s41591-026-04204-0. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.